前列腺穿刺组织中基因组风险评分的异质性及MRI靶向穿刺的影响
本研究基于2项前瞻性前列腺癌试验,对78例患者的224条阳性穿刺芯进行3种基因组预后签名(Decipher、CCP、GPS)检测,发现不同穿刺芯的基因组评分存在变异,风险分类可变化21%至62%。MRI靶向穿刺或对最高级别穿刺芯进行检测在72%至87%的病例中可获得最高基因组风险水平。
要点
- 不同穿刺芯的基因组评分存在异质性,风险分类变化21%至62%。
- MRI靶向穿刺或检测最高级别穿刺芯在多数病例中可获最高基因组风险。
- 穿刺级别和MRI风险水平越高,基因组评分越高(p<0.001)。
核心结论
- 无论使用何种基因组签名,不同穿刺芯的基因组风险评估均存在变异。
- MRI靶向穿刺或对最高级别穿刺芯进行检测在多数病例中可获得最高基因组风险水平。
研究设计与样本
- 研究纳入来自2项前瞻性前列腺癌试验的78例接受多参数MRI和MRI靶向穿刺的患者,对224条阳性穿刺芯进行基因组 profiling。
- 评估肿瘤分级、MRI风险与每种基因组签名风险的关系,并分析不同穿刺芯间基因组风险评估的变异性。
主要发现
- 对于每种签名,更高的穿刺分级(p<0.001)和MRI风险水平(p<0.001)与更高的基因组评分相关。
- 不同穿刺芯的基因组评分存在变异,风险分类变化范围为21%至62%,取决于所用穿刺芯或签名。
- MRI靶向穿刺和检测最高级别穿刺芯分别在72%至84%和75%至87%的病例中(取决于签名)获得最高基因组风险水平。
临床怎么用
- 在前列腺穿刺组织基因组风险评估中,应考虑穿刺芯间的异质性。
- MRI靶向穿刺或优先检测最高级别穿刺芯可能有助于获取最高基因组风险信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Genomic prognostic signatures are used on prostate biopsy tissue for cancer risk assessment, but tumor heterogeneity and multifocality may be an issue. We evaluated the variability in genomic risk assessment from different biopsy cores within the prostate using 3 prognostic signatures (Decipher, CCP, GPS). MATERIALS AND METHODS: Men in this study came from 2 prospective prostate cancer trials of patients undergoing multiparametric magnetic resonance imaging and magnetic resonance imaging targeted biopsy with genomic profiling of positive biopsy cores. We explored the relationship among tumor grade, magnetic resonance imaging risk and genomic risk for each signature. We evaluated the variability in genomic risk assessment between different biopsy cores and assessed how often magnetic resonance imaging targeted biopsy or the current standard of care (profiling the core with the highest grade) resulted in the highest genomic risk level. RESULTS: In all, 224 positive biopsy cores from 78 men with prostate cancer were profiled. For each signature, higher biopsy grade (p <0.001) and magnetic resonance imaging risk level (p <0.001) were associated with higher genomic scores. Genomic scores from different biopsy cores varied with risk categories changing by 21% to 62% depending on which core or signature was used. Magnetic resonance imaging targeted biopsy and profiling the core with the highest grade resulted in the highest genomic risk level in 72% to 84% and 75% to 87% of cases, respectively, depending on the signature used. CONCLUSIONS: There is variation in genomic risk assessment from different biopsy cores regardless of the signature used. Magnetic resonance imaging directed biopsy or profiling the highest grade core resulted in the highest genomic risk level in most cases.
引用
- Punnen S, Stoyanova R, Kwon D, et al. Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy. J Urol. 2020. PMID: 33356482. doi:10.1097/JU.0000000000001559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。